Access to vital and innovative medicines
Addressing challenges of intellectual property rights

Provision of access to affordable innovative and vital medicines is a future key challenge to the sustainability of health and welfare systems. However, there is increasing debate highlighting a mismatch between the market-driven model of pharmaceutical innovation versus the affordability, quality and access to the final product. This session will consider whether the current intellectual property system is suitable for drug development and if and how we can amend and enforce rules and regulations to enhance transparency and better balance the power relations between the pharmaceutical industry and public healthcare systems.

Keynote presentation: Historical overview and reflection on the key challenges

ELLEN ‘T HOEN
Expert on Medicines Law & Policy

Panel discussion

The discussion will address the key challenges concerning intellectual property rights rules for access to medicines. Do patents increase innovation and productivity? Is a long-term patent justified? How can we make changes to IP rights protection without impeding our ability to foster innovation?

RAF MERTENS
Director-General, Belgian Health Care Knowledge Centre (KCE)

ANCELLA SANTOS QUINT’ANO
Senior Policy Advisor, Health Action International (HAI)

NATHALIE MOLL
Director-General, European Federation of Pharmaceutical Industries and Associations (EFPIA)

MARTIN SEYCHELL
Deputy-Director General, DG SANTE, European Commission

DUANE SCHULTHESS
Managing Director, Vital Transformation

DIARMAID MCDONALD
Lead organiser, Just Treatment, UK

Chaired by DAVID ROSE, Director, LACS Training

ORGANISED BY
Main Association of Austrian Social Security Institutions, National Institute of Health and Disability Insurance (NIHDI), Estonian Health Insurance Fund and Caisse Nationale de l’Assurance Maladie des Travaillleurs Salariés (CNAMTS) in cooperation with European Social Insurance Platform (ESIP)